Arvinas, Inc. (ARVN)
NASDAQ: ARVN · Real-Time Price · USD
7.33
+0.03 (0.41%)
Oct 26, 2026, 10:38 AM EDT - Market open
Arvinas Employees
Arvinas had 246 employees as of December 31, 2025. The number of employees decreased by 184 or 42.79% compared to the previous year. That makes Arvinas the 25,305th largest employer in the world and 3,243rd in the United States.
Employees
246
Change (1Y)
-184
Growth (1Y)
-42.79%
Revenue / Employee
$1,287,398
Profits / Employee
$37,805
Market Cap
479.28M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 246 | -184 | -42.79% |
| Dec 31, 2024 | 430 | -15 | -3.37% |
| Dec 31, 2023 | 445 | 30 | 7.23% |
| Dec 31, 2022 | 415 | 135 | 48.21% |
| Dec 31, 2021 | 280 | 101 | 56.42% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Valneva SE | 620 |
| Phathom Pharmaceuticals | 371 |
| Neurogene | 131 |
| CytomX Therapeutics | 69 |
| Oculis Holding AG | 60 |
| Eupraxia Pharmaceuticals | 49 |
| DiaMedica Therapeutics | 35 |
| Monopar Therapeutics | 22 |
ARVN News
- 19 days ago - Arvinas presents data from clinical trial of ARV-102 - TheFly
- 19 days ago - Arvinas Shares Novel Oculomotor and Biomarker Data from Phase 1 Clinical Trial of ARV-102 in Patients with Parkinson's Disease - GlobeNewsWire
- 24 days ago - Arvinas to Present Novel Biomarker Data from the Phase 1 Clinical Trial for ARV-102, a PROTAC LRRK2 Degrader, at the 2026 International Congress of Parkinson's Disease and Movement Disorders® - GlobeNewsWire
- 26 days ago - Arvinas Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 4 weeks ago - Arvinas announces first patient dosed in Phase 1/2 trial of ARV-6723 - TheFly
- 4 weeks ago - Arvinas Announces First Patient Dosed in Phase 1/2 Clinical Trial of ARV-6723, the Company's First Immuno-Oncology Candidate - GlobeNewsWire
- 5 weeks ago - Arvinas Transcript: Morgan Stanley 24th Annual Global Healthcare Conference - Transcripts
- 6 weeks ago - Arvinas Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference - Transcripts